A Case of Transmission of Bedaquiline- and Linezolid-Resistant Tuberculosis.

Anastasia Ushtanit, Irina Peretokina, Ludmila Krylova, Svetlana Safonova, Alexey Filippov, Danila Zimenkov

Abstract readCase Reports

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anastasia UshtanitCenter for High-Tech Bioeconomy, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.ORCID 0000-0002-7935-4316

Irina PeretokinaThe Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health, 107014 Moscow, Russia.

Ludmila KrylovaThe Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health, 107014 Moscow, Russia.

Svetlana SafonovaThe Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health, 107014 Moscow, Russia.

Alexey FilippovThe Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health, 107014 Moscow, Russia.

Danila ZimenkovCenter for High-Tech Bioeconomy, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.ORCID 0000-0002-2040-0904

Funding

Ministry of Science and Higher Education of the Russian Federation 075-15-2025-582

6 · The paper itself

Abstract

Tuberculosis is one of the hardest-to-treat bacterial diseases with a high capacity to develop antibiotic resistance. The treatment scheme based on bedaquiline and linezolid was introduced in Russia in 2014 and, since 2018, has been widely used for the treatment of resistant tuberculosis. In our study of clinical

Indexed as

Antitubercular AgentsDiarylquinolinesLinezolidMycobacterium tuberculosisTuberculosis, Multidrug-ResistantDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMutationWhole Genome SequencingAntitubercular AgentsbedaquilineDiarylquinolinesLinezolidbedaquilinedrug resistancelinezolidtransmissiontuberculosis

Identifiers

PMID42278438

DOI10.3390/ijms27114912

PMCPMC13256819

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.